MARKET

LGVN

LGVN

Longeveron Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.700
0.000
0.00%
After Hours: 3.660 -0.04 -1.08% 18:17 09/24 EDT
OPEN
3.630
PREV CLOSE
3.700
HIGH
3.700
LOW
3.593
VOLUME
27.80K
TURNOVER
--
52 WEEK HIGH
12.48
52 WEEK LOW
3.270
MARKET CAP
62.39M
P/E (TTM)
-18.6023
1D
5D
1M
3M
1Y
5Y
Longeveron Announces Dr. Jorge Ruiz as Speaker for Roundtable Discussion & Presentation at 2021 International Conference for Frailty & Sarcopenia Research
-- Jorge Ruiz, M.D., Associate Director for Clinical Affairs, Geriatric Research at the Miami VA Healthcare System, will present Longeveron’s Aging Frailty Phase 2b Trial Data -- National Institute on Aging-funded study showed significant, dose-dependent i...
GlobeNewswire · 4d ago
Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron
Photo by jesse orrico on Unsplash
Benzinga · 09/15 20:08
Longeveron partners with Kinesiometrics to create an App to measure physical responses to cell therapy
Longeveron (LGVN -2.4%) enters agreement with Kinesiometrics to provide a cutting-edge, digital data-driven solution for objective real-time measurement of functional capacity and quality of life in company's clinical studies. The data
Seekingalpha · 09/13 14:29
Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy
On the heels of Longeveron’s recent announcement showing Lomecel-B significantly increased walking distance in older, frail subjects, Longeveron intends to implement Kinesiometrics new digital data-driven solution for capturing activity levels, quality of ...
GlobeNewswire · 09/13 13:19
Longeveron's Phase 1 Study of Lomecel-B in Rare Heart Disease Shows Safety, Tolerability; Shares Rise
MT Newswires · 09/09 13:17
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients
Miami, Florida—September 9th, 2021— Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"),   a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threat
Benzinga · 09/09 12:42
LULU, FRO and PMCB among pre market gainers
Soligenix (NASDAQ:SNGX) +26% FDA Grants soligenix orphan drug designation for the treatment of T-cell lymphoma Eloxx Pharmaceuticals (NASDAQ:ELOX) +22% announces fast track designation for ELX-02 for the treatment of cystic fibrosis patients
Seekingalpha · 09/09 12:21
EXCLUSIVE: Longeveron's Lomecel-B Cell Therapy Meets Primary Safety Endpoint In Phase 1 Rare Congenital Heart Disease Study
Longeveron Inc.
Benzinga · 09/09 11:41
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LGVN. Analyze the recent business situations of Longeveron Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About LGVN
Longeveron Inc., formerly Longeveron LLC, is a clinical stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. Its lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring clinical trials in various indications, including Aging Frailty, Alzheimer's disease (AD), the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS) and hypoplastic left heart syndrome (HLHS). It is developing Lomecel-B as a therapy for Aging Frailty and is being designed to reduce inflammation associated with Aging Frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. It is conducting two multicenter trials in the United States (U.S.)

Webull offers kinds of Longeveron Inc stock information, including NASDAQ:LGVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LGVN stock methods without spending real money on the virtual paper trading platform.